Aftermarket performance by Verve strongest among seven biotechs listing this week
Although signs have emerged that investor demand for new biotech listings has cooled somewhat from a fever pitch early in the year, the seven IPOs priced between Wednesday night and Friday morning marked the most in a week since February.
The pace of IPOs has slowed this quarter compared with last, and double-digit aftermarket performances have become rarer. Although this week’s crop of new listings was larger than most, four of the seven still lost value in early trading...